abrdn Life Sciences Investors
HQL
80 hedge funds and large institutions have $73.9M invested in abrdn Life Sciences Investors in 2022 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 32 increasing their positions, 15 reducing their positions, and 3 closing their positions.
567% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 3
113% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 15
27% more funds holding
Funds holding: 63 → 80 (+17)
27% more capital invested
Capital invested by funds: $58.4M → $73.9M (+$15.5M)
3.74% more ownership
Funds ownership: 17.01% → 20.75% (+3.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1CP
1607 Capital Partners
Richmond,
Virginia
|
+$4.42M |
| 2 |
LSC
Logan Stone Capital
Chicago,
Illinois
|
+$2.3M |
| 3 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$2.26M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.72M |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$1.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NIM
Needham Investment Management
New York
|
-$2.19M |
| 2 |
SI
Stephens Inc
Little Rock,
Arkansas
|
-$1.12M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$796K |
| 4 |
LPL Financial
San Diego,
California
|
-$507K |
| 5 |
AAM
Advisors Asset Management
Monument,
Colorado
|
-$286K |
HQL Hedge Fund Activity: Q4 2022 in Review
80 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q4 2022, worth a combined $73.9M — up 27% from $58.4M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new HQL positions and 3 closed out — a net gain of 17 holders — while 32 added to existing stakes and 15 trimmed.
The largest buyer was 1607 Capital Partners, adding an estimated $4.42M. The largest seller was Needham Investment Management, cutting an estimated $2.19M.
- 80 institutional investors held abrdn Life Sciences Investors (HQL) as of Q4 2022, up from 63 in Q3 2022.
- Funds reported $73.9M of abrdn Life Sciences Investors stock for Q4 2022, up 27% quarter-over-quarter.
- 20 funds opened new abrdn Life Sciences Investors positions in Q4 2022 and 3 closed out, a net change of +17 holders.
- The largest abrdn Life Sciences Investors buyer in Q4 2022 was 1607 Capital Partners, an estimated $4.42M added.
- The largest abrdn Life Sciences Investors seller in Q4 2022 was Needham Investment Management, an estimated $2.19M sold.
Based on aggregated 13F filings for Q4 2022.